Use: Labeled indications
- INDICATIONS AND USAGE TOBREX ® (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria.
Full indications and usage US FDA label
INDICATIONS AND USAGE TOBREX ® (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.
Contraindications
- Hypersensitivity to any component
Contraindications (US label) US FDA label
CONTRAINDICATIONS TOBREX (tobramycin ophthalmic ointment) 0.3 % is contraindicated in patients with known hypersensitivity to any of its components.
Dosing: Adult
- External eye infections (ointment): Mild to moderate: half-inch ribbon 2 or 3 times daily. Severe: every 3 to 4 hours until improvement, then taper (label)
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION In mild to moderate disease, apply a half-inch ribbon into the affected eye(s) 2 or 3 times per day. In severe infections, instill a half-inch ribbon into the affected eye(s) every 3 to 4 hours until improvement, following which treatment should be reduced prior to discontinuation. How to Apply TOBREX (tobramycin ophthalmic ointment) 0.3%: 1.
Tilt your head back. 2. Place a finger on your cheek just under your eye and gently pull down until a ''V'' pocket is formed between your eyeball and your lower lid. 3. Place a small amount (about ½ inch) of TOBREX ® (tobramycin ophthalmic ointment) 0.3% in the ''V'' pocket. Do not let the tip of the tube touch your eye. 4.
Look downward before closing your eye.
Dosing: Altered kidney function
All tobramycin products registered in the Philippines are 0.3% eye drops or eye ointment. The ophthalmic label gives the same dose for everyone and no kidney adjustment. Injectable tobramycin, an aminoglycoside that needs kidney dosing and level monitoring, is not registered in the Philippine list and is not covered here.
Kidney function measure: Not applicable (topical ophthalmic product).
Show full dosing details
- CrCl ≥60 mL/min
- Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
- CrCl 30–59 mL/min
- Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
- CrCl 15–29 mL/min
- Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
- CrCl <15 mL/min (not on dialysis)
- Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
- Hemodialysis (intermittent)
- Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
- Peritoneal dialysis
- Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
- CRRT
- Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
- Dialyzable? Not relevant for ophthalmic use.
- Monitoring Clinical response of the eye infection; hypersensitivity. The label notes nephrotoxicity and ototoxicity with systemic aminoglycosides, not with eye use.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Eye use: no kidney adjustment (label).
- eGFR 30–59
- Eye use: no kidney adjustment (label).
- eGFR 15–29
- Eye use: no kidney adjustment (label).
- eGFR <15 (not on dialysis)
- Eye use: no kidney adjustment (label).
- Hemodialysis (intermittent)
- Eye use: no kidney adjustment.
- Peritoneal dialysis
- Eye use: no kidney adjustment.
- CRRT
- Eye use: no kidney adjustment.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Dosing: Pediatric
- Approved ages
- Safe and effective in children (label indications); not established under 2 months (label 8.4).
- Usual dose
- Same as adults.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 months has not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use: No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.
Dosage forms
Philippines
- Ophthalmic solution: 3 mg/mL
- Sterile ophthalmic solution: 3 mg/mL
- Ophthalmic ointment: 3 mg/g
- Sterile ophthalmic ointment: 3 mg/g
- Ophthalmic drops solution: 3 mg/mL
- Per gram sterile opthalmic ointment: 3 mg
Registered products in the Philippines
51 products registered with the Food and Drug Administration (FDA) Philippines list Tobramycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products51
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AccetobTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White HDPE bottle x 5 mL and 10 mL (net content) with white HDPE nozzle and cap (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-15471 | Jul 16, 2029 | |
AdtredTobramycin | 3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1’s) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPIPCO)Egypt | Sensomed Phil., Inc.Importer: Ambica International Corporation | DRP-8044-08 | Dec 5, 2028 | |
AguacinTobramycin Sulfate | 0.3% w/v Ophthalmic Solution5 mL HDPE Bottle with dropper tip and pilfer-proof cap (Box of 1's) | Rx | Bharat Parenteral LimitedIndia | Greencore Pharma Inc.Importer: SRS Life Sciences | DRP-1577-01 | Aug 3, 2027 | |
AguatobTobramycin (as sulfate) | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL and 10 mL HDPE Dropper Bottle (Box of 1's) | Rx | Scott-Edil Pharmacia LimitedIndia | Agua Visions TradingImporter: Greencore Pharma Inc. | DRP-13606-01 | Mar 16, 2028 | |
CinarexTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)Opaque (white) Low Density Polyethylene Bottle with white High Density Polyethylene Screw Cap and White LDPE Dropper x 5 mL (net content). (Box of 1's) | Rx | Beximco Pharmaceuticals LtdBangladesh | Aglobal Care, Inc. | DRP-10089 | Aug 13, 2029 | |
CONSACTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic SolutionLDPE Plastic Dropper-Tipped Bottle x 5mL Box of 1's | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Medilife Pharma, Inc. | DRP-1012 | Mar 8, 2030 | |
IkshatobTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with Green Cap x 6 mL (Box of 1's) | Rx | Daewoo Pharm. Co., Ltd.Republic of Korea | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-8138-03 | Oct 31, 2029 | |
MaxitobraTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with Green Cap x 6 mL (Box of 1's) | Rx | Daewoo Pharm. Co., Ltd.Republic of Korea | Qure Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-8138-02 | Oct 31, 2029 | |
MycinidinTobramycin | 3 mg/ mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Medchoice Vision Care Inc.Importer: Ambica International Corporation | DRP-8044-01 | Dec 5, 2028 | |
MycinidinTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL (Box of 1's) | Rx | Daewoo Pharm. Co., Ltd.Republic of Korea | Medchoice Vision Care Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-8138-05 | Oct 31, 2029 | |
MytocinTobramycin | 3 mg/mL Sterile Ophthalmic SolutionLDPE Dropper tipped bottle x 5 mL Box of 1's | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Vendiz Pharmaceuticals Inc. | DRP-2182 | Nov 11, 2029 | |
NebraTobramycin | 3mg/mL (0.3%) Sterile Ophthalmic Solution10 mL LDPE Bottle x 5mL Box of 1's | Rx | Remington Pharmaceutical Industries (Pvt.) Ltd.Pakistan | Ophthamed Pharma Corp. | DRP-12264 | Jun 16, 2031 | |
NeoconTobramycin | 3 mg/mL (0.3%) Ophthalmic SolutionLDPE Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Pharmabiz Solutions, Inc.Trader: Medilife Pharma, Inc. | DRP-1012-03 | Mar 8, 2030 | |
NoneTobramycin | 3 mg/ mL (0.3% w/v) Ophthalmic Solution (Eye Drops)HDPE Bottle x 5mL (Box of 1's) | Rx | e. L Laboratories, Inc.Philippines | Trader: Celsus Pharmaceuticals Phils., Inc. | DR-XY30560 | Feb 16, 2030 | |
NONETobramycin | 3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | PharmaVital Corp.Importer: Ambica International Corporation | DRP-8044-10 | Dec 5, 2028 | |
NoneTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic SolutionLDPE Plastic Dropper-Tipped Bottle x 5 mL Box of 1's | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Celsus Pharmaceuticals Phils., Inc.Trader: Medilife Pharma, Inc. | DRP-1012-04 | Mar 8, 2030 | |
NovamycinTobramycin (as sulfate) | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops).White LDPE Bottle Sealed with HDPE Cap x 15 mL (Box of 1's) | Rx | Pharmacos Exakta, S.A. De C.VMexico | Medinova Pharmaceutical, Inc., | DRP-12481 | Mar 3, 2028 | |
ObramicinTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White Opaque LDPE Bottle Sealed with HDPE Cap and White LDPE Dropper x 5 mL (Box of 1's) | Rx | World Medicine İlaç Sanayi Ve Ticaret A.Ş.Turkey | Orange Biotec, Inc. | DRP-14459 | Sep 7, 2028 | |
OcusynTobramycin | 3 mg/mL (0.3 % w/v Sterile Ophthalmic Solution (Eye Drops)LDPE White Plastic dropper tip bottle and HDPE cap x 5 mL (Box of 1's) | Rx | Laboratorios Ashford Lda.China | Marrion Pharma, Inc. | DRP-6030 | Oct 3, 2030 | |
OphthamycinTobramycin | 3 mg/ mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL LDPE Bottle (Box of 1's) | Rx | Samchundang Pharm Co., Ltd.Republic of Korea | Starpharm, Inc. | DRP-15489 | Aug 18, 2031 | |
OptobTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL Box of 1's | Rx | DAEWOO PHARM. CO., LTD.Republic of Korea | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corporation | DRP-8138-01 | Oct 31, 2029 | |
RamitobTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL (Box of 1's) | Rx | Daewoo Pharm. Co., Ltd.Republic of Korea | Bliss Pharma Distribution and Consultancy Corp. | DRP-8138 | Oct 31, 2029 | |
RaytobraxTobramycin | 3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE White Opaque Plastic Droptainer in 5 mL (net content) Box of 1's | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | RCL Ophthalmic SurgicalsImporter: Ambica International Corporation | DRP-8044-02 | Dec 5, 2028 | |
RetobracynTobramycin | 3 mg / mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) [Box of 1’s] | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Reta DrugImporter: Ambica International Corporation | DRP-8044-07 | Dec 5, 2028 | |
Retobracyn-RTobramycin | 3 mg / mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White HDPE bottle x 5 mL and 10 mL (net content) with white HDPE nozzle and cap (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-15471-02 | Jul 16, 2029 | |
T-MycinTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)5 mL White Opaque LDPE Plastic Dropper Bottle (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading Inc. | DRP-7729 | Mar 27, 2027 | |
Tobcin EyeTobramycin (as sulfate) | 3 mg/mL (0.3% w/v) Ophthalmic Solution5 mL white LDPE vial with HDPE cap and nozzle (Box of 1's) | Rx | East African (India) OverseasIndia | Airlife International Trading Corporation.Importer: Airlife International Trading Corporation | DRP-16121 | Nov 6, 2029 | |
TobiclearTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL (Box of 1's) | Rx | Daewoo Pharm. Co., Ltd.Republic of Korea | TGP Phama Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-8138-04 | Oct 31, 2029 | |
TobidinaTobramycin (as Sulfate) | 3 mg/g (0.3% w/w) Ophthalmic OintmentAluminum tube x 5 g (Box of 1's) | Rx | Indiana OphthalmicsIndia | Aglobal Care Inc.Importer: Aglobal Care, Inc. | DRP-13479 | Feb 27, 2028 | |
TobidinaTobramycin (as sulfate) | 3 mg/mL (0.3% w/v) Ophthalmic Solution5 mL sterile opaque plastic bottle with nozzle and cap (Box of 1's) | Rx | Indiana Ophthalmics.India | Aglobal Care, Inc. | DRP-15875 | Sep 25, 2029 | |
Tobra-VTobramycin | 3 mg/g (0.3% w/w) Ophthalmic OintmentAluminum collapsible tube x 3.5 g (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY35176 | Sep 12, 2027 | |
Tobra-VTobramycin | 3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution10 mL LDPE/HDPE Plastic Eye Dropper x 5 mL (Box of 1's) | Rx | El Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY33010 | Nov 26, 2027 | |
TobracareTobramycin | 3 mg / mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White HDPE bottle x 5 mL (net content) with white HDPE nozzle and cap (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc. | DRP-15471-01 | Jul 16, 2029 | |
TobracidTobramycin (as sulfate) | 3mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)LDPE Bottle with Translucent LDPE Nozzle Sealed with White Cap x 5 mL (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd. | DR-XY49458 | Jul 31, 2030 | |
TobracorTobramycin | 3 mg / mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-8044-05 | Dec 5, 2028 | |
TobragoTobramycin | 3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) Box of 1's | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation | DRP-8044-03 | Dec 5, 2028 | |
TobrakhrizTobramycin (as sulfate) | 3mg/mL (0.3% w/v) Ophthalmic Drops Solution (Eye Drops)PP Dropper Botlte with cap x 5 mL (Box of 1's) | Rx | Merit Organics LimitedIndia | Khriz Pharma Trading, Inc. | DR-XY49717 | May 13, 2031 | |
TobralcinTobramycin Sulfate | 0.3% w/v Ophthalmic Solution | Rx | Bharat Parenterals Limited | SRS Life Sciences Inc. | DRP-1577 | Aug 3, 2027 | |
TobraloupeTobramycin (as sulfate) | 3 mg/mL (0.3 % w/v) Ophthalmic Solution (Drops)5 mL HDPE Dropper Bottle (Box of 1's) | Rx | Scott-Edil Pharmacia LimitedIndia | PNJ Pharma EnterpriseImporter: Greencore Pharma Inc. | DRP-13606-02 | Mar 16, 2028 | |
TobralyfTobramycin | 3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-8044-04 | Dec 5, 2028 | |
TobranovTobramycin | 3 mg/mL (0.3% w/v) Ophthalmic Solution | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III Injectables)India | Medinova Pharmaceutical Inc.Trader: Unosource Pharma Ltd. | DRP-17603 | Feb 20, 2031 | |
TobrasafeTobramycin | 3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1’s) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Preventia Healthcare Inc.Importer: Ambica International Corporation | DRP-8044-06 | Dec 5, 2028 | |
TobrasaphTobramycin (as sulfate) | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL White HDPE Dropper Bottle and Single Pilfer Proof Ring Cap (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13181 | Dec 16, 2027 | |
TobraxaTobramycin Sulfate | 3mg/mL (0.3% w/v)LDPE Plastic Bottle x 5mL (Box of 1's) | Rx | Axa Parenterals Ltd.India | Brady Pharma Inc. | DRP-9895 | Jun 24, 2031 | |
TobrazinTobramycin Sulfate | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL and 10 mL HDPE Dropper Bottle (Box of 1's) | Rx | Scott-Edil Pharmacia LimitedIndia | Greencore Pharma Inc. | DRP-13606 | Mar 16, 2028 | |
TobrexTobramycin | 3 mg/g (0.3%) Sterile Ophthalmic OintmentAluminum Ophthalmic Tube x 3.5 g (Box of 1's) | Rx | Siegfried El Masnou, S.A.Spain | Importer: Novartis Healthcare Philippines, Inc. | DR-XY39418 | May 9, 2031 | |
TobrexTobramycin | 3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)Plastic droptainer x 5 mL (Box of 1's) | Rx | Alcon-Couvreur NVBelgium | Importer: Novartis Healthcare Philippines, Inc. | DR-XY7060 | Oct 25, 2029 | |
TobrinTobramycin | 3 mg/g (0.3% w/w) Sterile Ophthalmic Ointment.Collapsible Aluminum Tube x 5 g (Box of 1 tube) | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Ambica International Corporation | DRP-15064 | Apr 2, 2029 | |
TobrinTobramycin | 3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) Box of 1's | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Ambica International Corporation | DRP-8044 | Dec 5, 2028 | |
TomracinTobramycin | 3 mg/mL (0.3%) Sterile Ophthalmic Solution (Drops)5 mL LDPE Bottle (Box of 1's) | Rx | EBE PHARMACEUTICAL CO., LTD.China | AGLOBAL CARE, INC. | DRP-6646 | Jan 22, 2030 | |
ZartobTobramycin (as sulfate) | 3 mg per gram (0.3 % w/w) Sterile Opthalmic OintmentAluminum collapsible tube with plastic cap x 5 g (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ophtha Pharma Traders Inc.Importer: Medinova Pharmaceutical Inc. | DRP-13471-01 | Feb 27, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to TOBREX (tobramycin ophthalmic ointment) 0.3% occurs, discontinue use.
Adverse reactions
Common
- Local eye reactions: lid itching and swelling, conjunctival redness (under 3%)
Serious
- Hypersensitivity, including anaphylaxis; Stevens-Johnson syndrome, erythema multiforme (postmarketing)
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS: The most frequent adverse reactions to TOBREX (tobramycin ophthalmic ointment) 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with TOBREX ® (tobramycin ophthalmic ointment) 0.3%.
Postmarketing Experience: Additional adverse reactions identified from postmarketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme. The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy.
Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.
Monitoring parameters
- Clinical response of the eye infection; hypersensitivity. The label notes nephrotoxicity and ototoxicity with systemic aminoglycosides, not with eye use. Kidney
- Clinical response; signs of sensitivity
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy: Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers: Because of the potential for adverse reactions in nursing infants from TOBREX ® (tobramycin ophthalmic ointment) 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.
Pharmacokinetics
Key PK parameters
| Dialyzability kidney | Not relevant (ophthalmic) |
|---|
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.
Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Tobramycin Eye Drops 0.3%, 5 mL Bottle | ₱70.00–₱206.39Reference ₱160.00 | per bottle | DPRI procurement range |
| Tobramycin Eye Ointment 0.3%, 3.5 g Tube | ₱192.40–₱453.33Reference ₱192.40 | per tube | DPRI procurement range |
| 0.3% ophthalmic drop solution in 5 mL bottle | ₱345.00 | per bottle | PhilHealth GAMOT fixed fee |
| 0.3% ophthalmic ointment in 3.5 g tube | ₱519.50 | per tube | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Tobramycin |
| PNF listing | Eye Drops Solution: 0.3%, 5 mL bottle |
| PNF listing | Eye Ointment: 0.3%, 3.5 g tube |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. TOBREX · Novartis Pharmaceuticals Corporation [US FDA-approved label, version 7, October 26, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b66bba3-cf97-4a9c-b618-ba5f277f20f6
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Novartis Pharmaceuticals Corporation. (2026). TOBREX (tobramycin ophthalmic ointment) 0.3% [Prescribing information; US FDA-approved label, NDA050555, set ID 5b66bba3-cf97-4a9c-b618-ba5f277f20f6, version effective October 26, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b66bba3-cf97-4a9c-b618-ba5f277f20f6
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .